Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01745185
Recruitment Status : Completed
First Posted : December 10, 2012
Last Update Posted : April 4, 2017
Sponsor:
Information provided by (Responsible Party):
O & O Alpan LLC